It is a broadly described annual report of The IBN SINA Pharmaceutical Industry Limited in the year of 2012. The IPI had made a significant contribution in 2012 towards the National Exchequer by paying Tk. 327,638,187.00 as income tax and VAT. This is equivalent to 16.31% of the sales in the year under review. During the financial year, Company’s EPS stood at Tk. 4.13 which was Tk. 3.39 in 2011. Net Asset Value per share was Tk. 40.82 which was Tk. 47 .37 in 2011. Total Net Asset Value (NAV) in 2012 was Tk. 66,13,16,493.00 while in the previous year it was Tk. 61, 39, 15,103.00. Net Operating Cash Flow per Share (NOCFPS) was Tk. 5.70 as against Tk. 7.50 in the previous year. ln2012, the total sales of the Company reached Tk.2009.42 million which was 14.48 % higher than that of 2011. The earnings per share rose to Tk. 4.13. The net profit increased by 21.69 % than the last year. The external liability per one Taka shareholders equity reduced to Tk. 0.11.
The Company’s reserves and surplus rose to Tk. 169,571,732.00 which was Tk.148,105,315.00 in the previous year. After evaluating the Financial Statements of the Company in the year 2012, the Board of Directors proposed a stock dividend of 20% and the cash dividend of 15% per share of Tk.10 each.
More Annual Report of The IBN SINA Pharmaceutical Industry Limited:
- Annual Report 2010 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2011 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2012 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2013 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2014 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2017 of The IBN SINA Pharmaceutical Industry Limited
